Key facts
- Affection Animal Pharmaceuticals’s last known valuation is $363.2M (Sep 2022).
- It has raised $43.7M; the latest was Later Stage VC ($13.7M) in Jan 2025.
- Notable investors include SND Ventures Group, Suzhou Guofa Venture Capital, GSR United Capital, New Alliance Capital, Haihe River Industry Fund — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Affection Animal Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Affection Animal Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Affection Animal Pharmaceuticals
Developer of pet vaccines intended to enhance pet health condition. The company's products include veterinary biological products and veterinary chemical drugs, enabling pet families to protect pets from serious diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Suzhou, China
- Founded
- 2018
- Ownership
- Privately Held (backing)
Affection Animal Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Affection Animal Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Affection Animal Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.